A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia

This pilot study is testing whether adding venetoclax — a targeted cancer drug — to a standard chemotherapy regimen (FLAG or CLAG) can improve outcomes for people newly diagnosed with secondary acute myeloid leukemia (AML). Secondary AML develops from a prior blood disorder or as a result of earlier cancer treatments. **You may be eligible if:** - You have a newly confirmed diagnosis of secondary acute myeloid leukemia (AML), which includes AML that developed from a prior blood condition (like MDS, aplastic anemia, or myeloproliferative neoplasm), or AML that arose after prior cancer therapy - You have not previously been treated for AML - Your organ function and blood counts are adequate for chemotherapy **You may NOT be eligible if:** - You have previously received treatment for AML - You have significant health conditions that prevent you from tolerating intensive chemotherapy - You do not meet the specific diagnostic criteria for secondary AML Talk to your doctor to see if this trial is right for you.